The prognostic role of gene polymorphisms in patients with indolent non-Hodgkin lymphomas and mantle-cell lymphoma receiving bendamustine and rituximab: results of the 5-year follow-up study

The variability in disease outcome for indolent non-Hodgkin lymphomas (iNHL) and mantle-cell lymphoma (MCL) could be related to single nucleotide polymorphisms (SNPs) in genes that affect immune and inflammatory response. We investigated SNPs that could have a prognostic role for patients receiving bendamustine and rituximab (BR). All samples were genotyped for the IL-2 (rs2069762), IL-10 (rs1800890, rs10494879), VEGFA (rs3025039), IL-8 (rs4073), CFH (rs1065489) and MTHFR (rs1801131) SNPs by allelic discrimination assays using TaqMan SNP Genotyping Assays. We report a long-term follow-up analysis of 79 iNHL and MCL patients that received BR. Overall response rate was 97.5% (CR rate 70.9%). After a median follow-up of 63 months, median PFS and OS were not reached. We report a significant association between SNP in IL-2 (rs2069762) and reduced PFS and OS (p<.0001). We suggest a role for cytokine SNPs in disease outcome, while SNPs seem not related to long-term toxicity or secondary malignancies.

[1]  A. Chen,et al.  Rethinking Oncologic Treatment Strategies with Interleukin-2 , 2023, Cells.

[2]  Longlong Luo,et al.  The application of Interleukin-2 family cytokines in tumor immunotherapy research , 2023, Frontiers in Immunology.

[3]  Shiaw-Yih Lin,et al.  Tumor microenvironment: barrier or opportunity towards effective cancer therapy , 2022, Journal of Biomedical Science.

[4]  Yan-Ruide Li,et al.  Target tumor microenvironment by innate T cells , 2022, Frontiers in Immunology.

[5]  A. Rosenwald,et al.  The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms , 2022, Leukemia.

[6]  Jian Sun,et al.  New therapeutic strategies based on biasing IL-2 mutants for cancers and autoimmune diseases. , 2022, International immunopharmacology.

[7]  I. Lossos,et al.  An international analysis evaluating frontline bendamustine with rituximab in extranodal marginal zone lymphoma , 2022, Blood advances.

[8]  Habibe Kurt,et al.  CD5 expression in marginal zone lymphoma predicts differential response to rituximab or bendamustine/rituximab , 2021, Leukemia & lymphoma.

[9]  E. Cencini,et al.  The Role of Tumor-Associated Macrophages in Hematologic Malignancies , 2021, Cancers.

[10]  I. Matsumura,et al.  Low absolute lymphocyte count is a poor prognostic factor for untreated advanced follicular lymphoma treated with rituximab plus bendamustine: results of the prospective phase 2 CONVERT trial , 2021, International Journal of Hematology.

[11]  Xiwei Wu,et al.  Cytokine gene polymorphisms are associated with response to blinatumomab in B‐cell acute lymphoblastic leukemia , 2021, European journal of haematology.

[12]  S. Nonogaki,et al.  Single nucleotide variants in immune-response genes and the tumor microenvironment composition predict progression of mantle cell lymphoma , 2021, BMC Cancer.

[13]  S. Mousa,et al.  The Influence of Interleukin-2 Gene Polymorphisms on the Risk and Clinical Outcome of Non-Hodgkin Lymphoma , 2021, Indian Journal of Hematology and Blood Transfusion.

[14]  M. Ghielmini,et al.  Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  S. Nonogaki,et al.  An integrative microenvironment approach for follicular lymphoma: roles of inflammatory cell subsets and immune-response polymorphisms on disease clinical course , 2020, Oncotarget.

[16]  A. Salar,et al.  Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  C. Chang,et al.  Leukemic Non-nodal Mantle Cell Lymphoma: Diagnosis and Treatment , 2019, Current Treatment Options in Oncology.

[18]  F. Merli,et al.  Early Progression As a Predictor of Survival in Marginal Zone Lymphomas: An Analysis from the FIL-NF10 Study. , 2019, Blood.

[19]  A. Poggi,et al.  Anti-cancer Therapies Employing IL-2 Cytokine Tumor Targeting: Contribution of Innate, Adaptive and Immunosuppressive Cells in the Anti-tumor Efficacy , 2018, Front. Immunol..

[20]  E. Cencini,et al.  Efficacy and safety of rituximab plus bendamustine for gastric marginal zone lymphoma , 2018, Leukemia & lymphoma.

[21]  L. Rigacci,et al.  Study of gene polymorphisms as predictors of treatment efficacy and toxicity in patients with indolent non‐hodgkin lymphomas and mantle cell lymphoma receiving bendamustine and rituximab , 2018, British journal of haematology.

[22]  P. McKay,et al.  Guideline for the management of mantle cell lymphoma , 2018, British journal of haematology.

[23]  S. Mehrotra,et al.  IL-2 and Beyond in Cancer Immunotherapy. , 2018, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[24]  J. Castillo,et al.  Late infections and secondary malignancies after bendamustine/rituximab or RCHOP/RCVP chemotherapy for B‐cell lymphomas , 2018, American journal of hematology.

[25]  L. Vidal,et al.  Bendamustine‐associated infections—systematic review and meta‐analysis of randomized controlled trials , 2017, Hematological oncology.

[26]  Juan F. García,et al.  Long-term results of a phase 2 study of rituximab and bendamustine for mucosa-associated lymphoid tissue lymphoma. , 2017, Blood.

[27]  F. Cavalli,et al.  A MALT lymphoma prognostic index. , 2017, Blood.

[28]  L. Leoncini,et al.  Evaluation of the prognostic role of tumour‐associated macrophages in newly diagnosed classical Hodgkin lymphoma and correlation with early FDG‐PET assessment , 2017, Hematological oncology.

[29]  W. Klapper,et al.  Potentiating the activity of rituximab against mantle cell lymphoma in mice by targeting interleukin-2 to the neovasculature. , 2015, Leukemia research.

[30]  P. Fichna,et al.  Polymorphic variant at the IL2 region is associated with type 1 diabetes and may affect serum levels of interleukin-2 , 2013, Molecular Biology Reports.

[31]  K. Kuliczkowski,et al.  VEGF and bFGF Gene Polymorphisms in Patients with Non-Hodgkin's Lymphoma , 2013, BioMed research international.

[32]  J. Cerhan,et al.  Germline variation in complement genes and event‐free survival in follicular and diffuse large B‐cell lymphoma , 2012, American journal of hematology.

[33]  Haihan Song,et al.  Interleukin 2 gene polymorphisms are associated with non-Hodgkin lymphoma. , 2012, DNA and cell biology.

[34]  J. Cerhan,et al.  Inherited genetic variation and overall survival following follicular lymphoma , 2012, American journal of hematology.

[35]  Shuangge Ma,et al.  Polymorphisms in immune function genes and non-Hodgkin lymphoma survival , 2012, Journal of Cancer Survivorship.

[36]  Elias Campo,et al.  The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. , 2011, Blood.

[37]  J. Cerhan,et al.  Prognostic significance of host immune gene polymorphisms in follicular lymphoma survival. , 2007, Blood.

[38]  J. Vestbo,et al.  Family based association analysis of the IL2 and IL15 genes in allergic disorders , 2006, European Journal of Human Genetics.

[39]  P. Solal-Céligny.  Follicular Lymphoma International Prognostic Index. , 2004, Current treatment options in oncology.

[40]  A. Alcina,et al.  Effects of the multiple sclerosis associated −330 promoter polymorphism in IL2 allelic expression , 2004, Journal of Neuroimmunology.